Attovia Therapeutics jumps in Nasdaq debut after upsized $289 million IPO

Attovia Therapeutics

05/08/2026 18:03

Updates
** Drug developer Attovia Therapeutics' ATTO.O shares jump as much as 33.8% in Nasdaq debut after upsized $289 million U.S. IPO 
** The stock opened at $21 apiece versus the $17 IPO price; last up 28.5% at $21.85
** San Carlos, California-based ATTO late on Tuesday sold 17 million shares in an upsized IPO at $17 apiece
** ATTO, which is developing treatments for immune-mediated diseases, had initially marketed about 12.5 million shares priced between $15 and $17 apiece
** Its lead programs include ATTO-1310, which is being developed to treat chronic pruritic diseases
** Morgan Stanley, Leerink Partners, Citigroup and RBC Capital Markets acted as joint book-running managers for the offering

(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))